Home » News » Drug Sponsors » Mylan notifies Perrigo of HSR filing regarding proposed acquisition

Mylan notifies Perrigo of HSR filing regarding proposed acquisition

Monday, April 13, 2015

Mylan, a global generics and specialty pharmaceutical company, has provided Perrigo, an Irish international manufacturer of over-the-counter pharmaceuticals, with notice of its filing of the pre-merger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.

Robert J. Coury, Mylan executive chairman, said, “As we continue to await for Perrigo’s board of directors’ deliberations to be complete, today’s filing represents another important step in our ongoing determination to make this compelling proposed combination a reality. We are eager to continue our prior discussions with Perrigo as soon as possible and to mutually agree on the way forward.”

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!